Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Inclusion Criteria:

* Undergone allogeneic cell transplantation ≥21 days prior to dosing
* Meet one of the below criteria:

1. AdV viremia DNA ≥10,000 copies/mL, OR
2. AdV viremia DNA results of ≥1,000 copies/mL, AND

1. has absolute lymphocyte count \<180/mm3, OR
2. has received T cell depletion OR
3. had a cord blood transplant.

Exclusion Criteria:

* Grade 3 or higher acute GVHD
* Ongoing therapy with high-dose systemic corticosteroids
* Uncontrolled viral (other than AdV), bacterial, or fungal infection(s)
* Pregnant or lactating female unwilling to discontinue nursing prior to randomization
* History of severe prior reactions to blood product transfusions

NOTE: Other protocol-defined inclusion/exclusion criterion may apply.